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Comparing risk factor associations between invasive breast cancers and possible precursorsmay further our under-
standing of factors related to initiation versus progression. Accordingly, among 190,325 postmenopausal participants
in the National Institutes of Health-AARP Diet and Health Study (1995–2011), we compared the association between
risk factors and incident ductal carcinoma in situ (DCIS; n = 1,453) with that of risk factors and invasive ductal carcino-
mas (n = 7,525); in addition, we compared the association between risk factors and lobular carcinoma in situ (LCIS;
n= 186) with that of risk factors and invasive lobular carcinomas (n = 1,191). Hazard ratios and 95% confidence inter-
vals were estimated frommultivariable Cox proportional hazards regression models. We used case-only multivariable
logistic regression to test for heterogeneity in associations. Younger age at menopause was associated with a higher
risk of DCIS but lower risks of LCIS and invasive ductal carcinomas (P for heterogeneity < 0.01). Prior breast biopsy
was more strongly associated with the risk of LCIS than the risk of DCIS (P for heterogeneity = 0.04). Increased risks
associated with use of menopausal hormone therapy were stronger for LCIS than DCIS (P for heterogeneity = 0.03)
and invasive lobular carcinomas (P for heterogeneity < 0.01). Associations were similar for race, age at menarche,
age at first birth, family history, alcohol consumption, and smoking status, which suggests that most risk factor asso-
ciations are similar for in situ and invasive cancers and may influence early stages of tumorigenesis. The differential
associations observed for various factors may provide important clues for understanding the etiology of certain
breast cancers.
breast cancer; DCIS; histology; LCIS; precursors; risk factors
Abbreviations: BMI, body mass index; CI, confidence interval; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HR, hazard
ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; MHT, menopausal
hormone therapy; NIH, National Institutes of Health.
Most invasive breast carcinomas arise fromwell-characterized
precursors, such as ductal carcinoma in situ (DCIS) and lobular
carcinoma in situ (LCIS). Statistics from the Surveillance, Epide-
miology, and End Results Program show that between 2004 and
2008, DCIS accounted for 83.8% of all breast carcinomas in
situ, with LCIS accounting for 11.4% (1). Invasive ductal carci-
noma (IDC) and invasive lobular carcinoma (ILC) accounted for
70.6% and 8.3% of all invasive breast cancers, respectively (1).
Multiple studies suggest that DCIS is a nonobligate pre-
cursor lesion and that most invasive breast tumors arise and
develop from this precursor lesion (2, 3). In contrast, LCIS is
thought to be a more general marker of the risk of invasive
breast cancer, because many of the cancers that occur after
a diagnosis of LCIS are of ductal histological type (2). Results
from molecular studies that suggested a clonal link of LCIS
with ILC have renewed interest in LCIS as a nonobligate precur-
sor lesion, as well as a risk indicator (4).
Comparative analyses of the associations of risk factors for
breast cancer with in situ and with invasive carcinomas have not
been definitively established. Studies of etiological heterogeneity
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in which researchers compare risk factors for in situ versus those
for invasive breast cancer, particularly with additional differenti-
ation by ductal versus lobular histological type, are limited (5–7).
Although breast cancer risk factors are likely to be important for
tumor initiation, risk factors such as menopausal hormone
therapy (MHT) (8) may also contribute to tumor progression
and may show differential associations with invasive breast
cancer compared with DCIS and LCIS (9). Identifying breast
cancer risk factor differences and similarities between andwithin
in situ and invasive carcinomas may help to further our under-
standing of disease etiology and progression.
The National Institutes of Health (NIH)-AARP Diet and
Health Study is a large prospective cohort study that facilitates
the analysis of risk relationships with specific tumor types,
including in situ versus invasive carcinomas.We previously re-
ported differences in risk factor associations by invasive histo-
logical types of breast carcinoma in this cohort (10, 11). In the
present study, we aimed to expand these findings. First, we com-
pared risk factor associations with DCIS to those with LCIS.We
then compared risk factor associations for DCIS and LCIS with
those observed for invasive breast tumors.
METHODS
Study population
We conducted this study using participants from the NIH-
AARP Diet and Health Study, a longitudinal cohort established
in 1995–1996 as previously described (12). Briefly, self-
administered, baseline questionnaires regarding health and nutri-
tion weremailed to 3.5millionmembers of the AARP (formerly,
the American Association of Retired Persons) who resided in 6
states (California, Florida, Louisiana, New Jersey, North Caroli-
na, and Pennsylvania) and 2 metropolitan areas (Atlanta, Geor-
gia; and Detroit, Michigan). These regions were chosen for their
large AARP populations and cancer registries with case ascer-
tainment rates of 90% or more. Of this population, 566,398
satisfactorily completed and returned the questionnaire (12).We
excluded participants with questionnaires completed by proxy
(n = 15,760), men (n = 325,171), women who had a self-
reported personal history of cancer other than nonmelanoma skin
cancer (n = 23,998), premenopausal women (n = 9,418),
women who reported extreme values for caloric intake (defined
as >2 interquartile ranges above the 75th percentile or below the
25th percentile of log-transformed intake; n = 1,703), and
women who had no follow-up time (n = 23). The final analytic
population included 190,325 postmenopausal women who were
cancer-free at baseline and who were followed up through
December 31, 2011. A second questionnaire was administered to
enrolled participants between 1996 and 1997, and additional risk
factor data were collected (n = 120,780). The NIH-AARP Diet
and Health Study was approved by the Special Studies Institu-
tional Review Board of the US National Cancer Institute. All
participants gave informed consent by virtue of completing and
returning the questionnaire.
Risk factors for breast cancer
All data on risk factors were self-reported at baseline except
a history of mammography, which was self-reported in the sec-
ond questionnaire (i.e., at least 1 mammogram in the past 3 years;
no or yes). Risk factors included age at study entry (<55,
55–59, 60–64, 65–69, or ≥70 years), race (white or nonwhite),
age at menarche (≤12, 13–14, or ≥15 years), age at first birth
(<20, 20–24, 25–29, or ≥30 years or nulliparous), and type of
menopause (natural, which was further stratified into catego-
ries of <45, 45–49, 50–54, or ≥55 years; surgical, which was
defined as cessation of menstrual cycle because of a surgical
procedure; and medical or unknown, which was defined as
cessation of menstrual cycle because of medical reasons or
information not captured in the questionnaire). Use of MHT
was defined as a combination of use of any MHT formula-
tion and duration of use (never; former; current, <5 years; cur-
rent, 5–9 years; or current, ≥10 years). Additional risk factors
that were investigated included a family history of breast can-
cer in a first-degree female relative (no or yes), past breast
biopsy (no or yes), alcohol consumption during the 12 months
before completion of the questionnaire (0, 0.01–10.00,
10.01–20.00, or ≥20.01 g/day; estimated from the amount and
frequency consumed, as previously described) (13), smoking
status (never, former, or current), bodymass index (BMI (calcu-
lated as weight (kg)/height (m)2) <18.5, 18.5–24.9, 25–29.9,
30.0–34.9, or ≥35.0) (14), educational level (no college vs.
some college or more), and frequency of vigorous physical
activity (never or rarely, 1–3 times/month, 1–2 times/week,
3–4 times/week, or≥5 times/week).
Ascertainment of breast cancer
Incident cases of in situ and invasive breast carcinomas were
identified through probabilistic linkage to cancer registries in
the 8 states in the cohort, as well as 3 in nearby states to which
participants tended to move (Arizona, Nevada, and Texas). In a
previous validation study of this cohort,Michaud et al. (15) esti-
mated that 90% of all incident cancers were reported in states in
which participants resided at baseline. Behavior and histology
codes from the International Classification of Diseases for
Oncology, Third Edition, were used to define invasive (behav-
ior code 3), ductal (histology code 8500/3 or 8523/3), and lob-
ular (histology code 8520/3 or 8524/3) histological types (16).
To identify in situ disease that corresponded with the invasive
codes included in this analysis, we defined DCIS and LCIS
using the same histology codes and with the behavior code 2.
Statistical analysis
We estimated hazard ratios and 95% confidence intervals
using Cox proportional hazards regression models with age
as the time metric. Women were observed from the date on
which the 1995–1996 study questionnaire was returned until
the earliest of the following events occurred: movement out
of the defined catchment area, death, diagnosis, or the end of
follow-up (December 31, 2011). We used the Wald test to
test for a linear trend between risk factors for breast cancer
and risk of breast cancer. In multivariable models in which
we evaluated histology-specific risk, women were censored
at the date of diagnosis of other histological subtypes of breast
cancer. Case-only logistic regression was used to test for statis-
tical heterogeneity in the associations of risk factors with DCIS
versus those with LCIS; associations with DCIS versus
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those with IDC; and association with LCIS versus ILC. All
multivariable models included adjustments for established risk
factors for breast cancer that were determined in previous stud-
ies of postmenopausal breast cancer (10). Participants withmiss-
ing data on covariates were retained in a designated “unknown”
category in multivariable models.We repeated sensitivity analy-
ses in a subset of women who completed the second question-
naire and who had a mammogram within 3 years of it (n =
120,780). In additional sensitivity analyses, we examined
whether the relationship between BMI and risk of the histologic
subtypes varied by MHT use. We conducted analyses using
SAS, version 9.3 (SAS Institute, Inc., Cary, North Carolina).
Statistical tests were 2-sided. P values≤ 0.05 were considered
statistically significant.
RESULTS
Characteristics of study participants
A total of 1,453 DCIS, 186 LCIS, 7,525 IDC, and 1,191 ILC
were diagnosed among these 190,325 postmenopausal women
during an average of 13.3 (standard deviation, 4.3) years of
follow-up. The distributions of breast cancer risk factors and
patient characteristics stratified by cancer histological subtype
are presented in Web Table 1 (available at https://academic.
oup.com/aje).
Participant characteristics and risks of DCIS and LCIS
Relationships of participant characteristics with risks of DCIS
and LCIS are shown in Table 1. We observed significant het-
erogeneity in risk factor associations of DCIS and of LCIS
with age atmenopause,MHT use, and a history of breast biopsy
(Table 1). Specifically, compared with women whose age at
natural menopause was 50–54 years, those who were younger
natural menopause (<45 years) had a higher risk of DCIS (haz-
ard ratio (HR) = 1.30; 95% confidence interval (CI): 1.06,
1.61) but not LCIS (HR = 0.71; 95% CI: 0.37, 1.34; P for het-
erogeneity < 0.01). Furthermore, the higher risk associated
with MHT use was significantly stronger for LCIS than for
DCIS (P for heterogeneity= 0.03). CurrentMHT usewas asso-
ciated with at least 2.5-fold higher risk of LCIS, irrespective of
duration of use (for <5 years of use, HR = 2.59, 95% CI: 1.65,
4.05; for 5–9 years of use, HR = 3.63, 95% CI: 2.36, 5.59; and
for ≥10 years of use, HR = 2.71, 95% CI: 1.70, 4.30). In con-
trast, the hazard ratios for the association between current MHT
use and DCIS were 1.44 (95% CI: 1.22, 1.71), 1.76 (95% CI:
1.50, 2.07), and 1.57 (95%CI: 1.35, 1.82) for<5, 5–9, and≥10
years of use, respectively.Women who had a history of a previ-
ous breast biopsy were more likely to be diagnosed with LCIS
(HR = 2.21; 95% CI: 1.65, 2.96) than with DCIS (HR = 1.54,
95% CI: 1.38, 1.72; P for heterogeneity = 0.04) (Table 1). Dif-
ferences between risk factor associations for DCIS and
LCISwere not observed for age at entry, race, age at menarche,
age at first birth, a family history of breast cancer, or alcohol or
smoking (for DCIS vs. LCIS, P for heterogeneity > 0.05 for
each risk factor). Furthermore, differences were not observed
for educational level and frequency of vigorous physical activ-
ity (data not shown).
Participant characteristics and risk of in situ versus
invasive breast cancers
Next, we examined the relationships of participant character-
istics with risks of in situ breast cancers and invasive breast can-
cer. Similar patterns of association for the risks of DCIS and
IDCwere observed for most risk factors, including age, race, age
at menarche, age at first birth, MHT use, a family history of breast
cancer, and histories of alcohol and smoking (P for heterogeneity
> 0.05) (Table 1). Similar patterns were also observed for educa-
tional level and frequency of vigorous physical activity (data not
shown). Younger age at natural menopause was associated with
a higher risk of DCIS, as noted before, but with a lower risk of
IDC (P for heterogeneity< 0.01). A slightly stronger association
with a history of breast biopsy was observed for the risk of DCIS
(HR = 1.54, 95% CI: 1.38, 1.72) compared with the risk of IDC
(HR = 1.38, 95%CI: 1.31, 1.45;P for heterogeneity= 0.05).
In a similar manner, when we compared risk relationships
for LCIS and ILC, we observed few differences. Heterogene-
ity in the risk of LCIS versus ILC was suggested for age at
entry (P for heterogeneity< 0.01). In addition, MHT use was
more strongly associated with LCIS than with ILC (P for
heterogeneity < 0.01). Whereas risk of LCIS increased more
than 2.5-fold with current MHT use, the hazard ratios for the
association between ILC and with current MHT use were
1.38 (95% CI: 1.15, 1.66), 1.42 (95% CI: 1.18, 1.71), and
1.35 (95% CI: 1.14, 1.59) for <5, 5–9, and ≥10 years of
use, respectively (Table 1).
Sensitivity analyses
As has been previously shown in this study population
(17) and in other study populations (18, 19), elevated BMI is
associated with a higher risk of postmenopausal breast can-
cer that is particularly strong among those who have never
used MHT (17, 20). Consistent with these studies, we also
observed a significant interaction between BMI and MHT
use with respect to risk (for current vs. noncurrent MHT users,
P for interaction < 0.01). Therefore, we investigated the rela-
tionships between BMI and the risks of in situ and invasive
breast cancers stratified by MHT use (Table 2). In general, risks
of in situ and invasive ductal and lobular breast cancers were
greatest among overweight and obese women compared with
leanwomen (Table 2), particularly amongwomenwho had never
used MHT (for all histological types, P for trend <0.01).
Among never users of MHT, the magnitude of association was
strongest for LCIS (for BMI ≥35 versus 18.5–24.9, HR =
3.08, 95% CI: 1.26, 7.54). The strength of this association
was higher among former users of MHT, but no clear pat-
tern of association was observed among current MHT users
(Table 2).
To attempt to account for potential bias as a result of screening
practices thatmay have influenced risk factor relationshipswithin
this population, we conducted analyses among the 120,780
womenwho had a mammogram in the 3 years before adminis-
tration of the 1996–1997 questionnaire (Table 3). Overall,
the findings within this population were consistent with those
in the full cohort, although the P values for heterogeneity were
somewhat attenuated by the reduced sample size. It is notable
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Table 1. Associations of Participant CharacteristicsWith Risks of In Situ and Invasive Breast Cancers, by Histological Type, Among Postmenopausal Women (n = 190,325), National
Institutes of Health-AARPDiet and Health Study Cohort, 1995–2011a
Characteristic
DCIS (n = 1,453) LCIS (n = 186) DCIS vs. LCIS
P for Heterogeneity
IDC (n = 7,525) DCIS vs. IDC
P for Heterogeneity
ILC (n = 1,191) LCIS vs. ILC
P for HeterogeneityHR 95%CI HR 95%CI HR 95%CI HR 95%CI
Age at entry, years 0.35 0.68 <0.01
<55 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
55–59 1.03 0.83, 1.27 0.86 0.53, 1.37 1.12 1.02, 1.23 0.92 0.72, 1.17
60–64 1.09 0.87, 1.37 1.06 0.61, 1.85 1.16 1.05, 1.28 1.05 0.81, 1.36
65–69 1.15 0.90, 1.47 1.04 0.54, 2.00 1.24 1.11, 1.39 1.24 0.95, 1.64
≥70 1.08 0.73, 1.60 1.67 0.60, 4.71 1.29 1.10, 1.53 1.07 0.70, 1.62
P for trend 0.24 0.54 <0.01 0.03
Race 0.83 0.06 0.35
White 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Nonwhite 1.07 0.90, 1.28 1.03 0.62, 1.71 0.90 0.83, 0.97 0.79 0.64, 0.99
Age at menarche, years 0.36 0.24 0.57
≤12 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
13–14 1.06 0.95, 1.18 0.85 0.62, 1.16 0.98 0.93, 1.02 1.04 0.92, 1.18
≥15 0.83 0.68, 1.01 0.94 0.56, 1.58 0.91 0.84, 0.99 0.97 0.78, 1.19
P for trend 0.42 0.46 0.03 0.89
Age at first birth, years 0.80 0.06 0.62
<20 0.85 0.72, 1.00 0.91 0.57, 1.44 0.95 0.89, 1.02 0.78 0.64, 0.94
20–24 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25–29 1.18 1.03, 1.37 1.40 0.95, 2.06 1.05 0.99, 1.12 1.38 1.19, 1.60
≥30 or nulliparous 1.39 1.22, 1.59 1.37 0.94, 2.00 1.21 1.14, 1.28 1.43 1.23, 1.65
P for trend <0.01 0.03 <0.01 <0.01
Age at menopause, years <0.01 <0.01 0.06
<45 1.30 1.06, 1.61 0.71 0.37, 1.34 0.77 0.69, 0.85 0.77 0.60, 0.99
45–49 1.00 0.84, 1.18 0.61 0.39, 0.96 0.93 0.87, 1.00 0.83 0.70, 0.99
50–54 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
≥55 1.23 0.99, 1.53 0.70 0.37, 1.33 1.20 1.10, 1.32 1.19 0.96, 1.48
Surgical 0.93 0.81, 1.08 0.41 0.28, 0.59 0.74 0.70, 0.79 0.72 0.62, 0.84
Unknown 1.71 1.31, 2.22 1.04 0.53, 2.05 0.91 0.79, 1.05 0.68 0.46, 1.02
P for trend 0.63 <0.01 <0.01 <0.01
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Table 1. Continued
Characteristic
DCIS (n = 1,453) LCIS (n = 186) DCIS vs. LCIS
P for Heterogeneity
IDC (n = 7,525) DCIS vs. IDC
P for Heterogeneity
ILC (n = 1,191) LCIS vs. ILC
P for HeterogeneityHR 95%CI HR 95%CI HR 95%CI HR 95%CI
MHT use 0.03 0.13 <0.01
Never 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Former 1.14 0.93, 1.39 1.60 0.88, 2.92 1.05 0.96, 1.14 0.85 0.67, 1.07
Current (<5 years) 1.44 1.22, 1.71 2.59 1.65, 4.05 1.22 1.13, 1.32 1.38 1.15, 1.66
Current (5–9 years) 1.76 1.50, 2.07 3.63 2.36, 5.59 1.41 1.31, 1.52 1.42 1.18, 1.71
Current (≥10 years) 1.57 1.35, 1.82 2.71 1.70, 4.30 1.35 1.26, 1.44 1.35 1.14, 1.59
P for trend <0.01 <0.01 <0.01 <0.01
Family history of breast cancer 0.34 0.19 0.92
No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Yes 1.63 1.42, 1.86 1.15 0.76, 1.75 1.47 1.38, 1.56 1.28 1.09, 1.50
Breast biopsy 0.04 0.05 0.08
No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Yes 1.54 1.38, 1.72 2.21 1.65, 2.96 1.38 1.31, 1.45 1.60 1.42, 1.80
Alcohol consumption, g/day 0.46 0.39 0.60
0 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
0.01–10.00 1.05 0.93, 1.19 1.27 0.88, 1.83 1.03 0.97, 1.08 1.08 0.94, 1.24
10.01–20.00 1.02 0.84, 1.25 1.55 0.92, 2.63 1.11 1.02, 1.21 1.13 0.91, 1.40
≥20.01 1.08 0.87, 1.34 1.11 0.57, 2.14 1.26 1.15, 1.38 1.43 1.15, 1.79
P for trend 0.50 0.33 <0.01 <0.01
Smoking status 0.78 0.52 0.38
Never 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Former 1.03 0.92, 1.16 0.89 0.64, 1.23 1.11 1.05, 1.17 1.05 0.93, 1.20
Current 1.02 0.87, 1.20 0.84 0.52, 1.35 1.13 1.05, 1.21 1.26 1.07, 1.50
P for trend 0.62 0.41 <0.01 0.01
Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ;
MHT, menopausal hormone therapy.
a All analyses were adjusted for age at entry, race, body mass index, smoking status, alcohol consumption, age at menarche, age at first birth, age at menopause, MHT use and duration of
use, past breast biopsy, family history of breast cancer in a first-degree female relative, educational level, and frequency of vigorous physical activity.
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Table 2. Associations of BodyMass IndexWith Risks of In Situ and Invasive Breast Cancers, by Menopausal Hormone Therapy Use and Histological Type, Among Postmenopausal Women,
National Institutes of Health-AARPDiet and Health Study Cohort, 1995–2011a
MHT Use
Category
and BMIb
Total
DCIS LCIS DCIS vs. LCIS
P for Heterogeneity
IDC DCIS vs. IDC
P for Heterogeneity
ILC LCIS vs. ILC
P for HeterogeneityNo. HR 95%CI No. HR 95%CI No. HR 95%CI No. HR 95%CI
Overallc 190,325 1,453 186 0.28 7,525 0.65 1,191 0.45
<18.5 0.78 0.46, 1.32 –d 0.80 0.63, 1.01 0.58 0.30, 1.12
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 1.07 0.95, 1.21 0.85 0.60, 1.22 1.12 1.06, 1.18 1.08 0.94, 1.23
30.0–34.9 1.09 0.93, 1.29 1.41 0.92, 2.15 1.24 1.16, 1.33 1.12 0.93, 1.34
≥35.0 1.25 1.02, 1.54 1.20 0.67, 2.16 1.44 1.32, 1.57 1.25 0.99, 1.57
P for trend 0.02 0.12 <0.01 0.02
Never users 87,271 530 47 0.21 3,145 0.97 503 0.42
<18.5 0.74 0.27, 1.99 –d 0.95 0.66, 1.35 0.68 0.25, 1.84
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 1.26 1.02, 1.56 1.01 0.45, 2.23 1.27 1.16, 1.39 1.25 1.00, 1.55
30.0–34.9 1.37 1.06, 1.77 2.00 0.87, 4.65 1.41 1.27, 1.57 1.26 0.96, 1.66
≥35.0 1.48 1.10, 2.00 3.08 1.26, 7.54 1.62 1.43, 1.83 1.64 1.21, 2.23
P for trend <0.01 <0.01 <0.01 <0.01
Former users 17,690 121 14 0.28 646 0.67 83 0.27
<18.5 –d 0.44 0.14, 1.38 1.05 0.14, 7.74
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 1.40 0.89, 2.22 1.44 0.41, 5.12 0.99 0.82, 1.19 1.13 0.66, 1.94
30.0–34.9 1.91 1.13, 3.23 1.82 0.41, 8.01 1.18 0.94, 1.48 1.62 0.86, 3.08
≥35.0 1.83 0.93, 3.62 1.50 1.13, 1.99 1.78 0.75, 4.21
P for trend 0.01 0.92 <0.01 0.06
Current users 84,820 798 125 0.31 3,723 0.17 604 0.58
<18.5 0.87 0.47, 1.64 –d 0.73 0.53, 1.02 0.47 0.17, 1.26
18.5–24.9 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25.0–29.9 0.96 0.82, 1.13 0.79 0.51, 1.21 1.05 0.97, 1.13 0.98 0.81, 1.18
30.0–34.9 0.83 0.65, 1.07 1.27 0.75, 2.15 1.12 1.01, 1.24 0.96 0.73, 1.26
≥35.0 0.99 0.71, 1.38 0.70 0.28, 1.76 1.24 1.08, 1.44 0.76 0.49, 1.18
P for trend 0.40 0.97 <0.01 0.57
Abbreviations: BMI, bodymass index; CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular
carcinoma in situ; MHT, menopausal hormone therapy.
a All analyses were adjusted for age at entry, race, smoking status, alcohol consumption, age at menarche, age at first birth, age at menopause, past breast biopsy, family history of breast
cancer in a first-degree female relative, educational level, and frequency of vigorous physical activity.
b BMI was calculated as weight (kg)/height (m)2.
c Additionally adjusted for MHT use and duration.
d There were an insufficient number of cases to estimate the HR.
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Table 3. Associations of Participant CharacteristicsWith Risks of In Situ and Invasive Breast Cancers, by Histological Type, Among Postmenopausal WomenWho Have Had aMammogram
(n = 120,780)a, National Institutes of Health-AARPDiet and Health Study Cohort, 1995–2011b
Characteristic
DCIS (n = 865) LCIS (n = 113) DCIS vs. LCIS
P for Heterogeneity
IDC (n = 4,592) DCIS vs. IDC
P for Heterogeneity
ILC (n = 734) LCIS vs. ILC
P for HeterogeneityHR 95%CI HR 95%CI HR 95%CI HR 95%CI
Age at entry, years 0.72 0.22 0.94
<55 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
55–59 0.97 0.72, 1.32 1.44 0.68, 3.06 1.09 0.96, 1.25 1.20 0.85, 1.70
60–64 1.28 0.92, 1.76 1.57 0.68, 3.65 1.14 0.99, 1.31 1.36 0.93, 1.97
≥65 1.26 0.89, 1.78 1.44 0.57, 3.65 1.24 1.06, 1.44 1.52 1.02, 2.27
P for trend 0.07 0.58 <0.01 0.03
Race 0.41 0.29 0.90
White 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Nonwhite 1.08 0.85, 1.38 0.83 0.38, 1.80 0.94 0.84, 1.05 0.86 0.64, 1.14
Age at menarche, years 0.55 0.24 0.98
≤12 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
13–14 1.11 0.97, 1.28 1.02 0.69, 1.51 0.99 0.94, 1.06 1.02 0.86, 1.17
≥15 0.83 0.63, 1.08 1.04 0.53, 2.05 0.89 0.80, 0.99 0.96 0.73, 1.25
P for trend 0.87 0.91 0.12 0.84
Age at first birth, years 0.29 0.04 0.32
<20 0.79 0.63, 0.98 1.15 0.63, 2.09 0.97 0.89, 1.06 0.76 0.59, 0.98
20–24 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
25–29 1.21 1.01, 1.45 1.75 1.07, 2.86 1.07 0.98, 1.16 1.42 1.17, 1.71
≥30 or nulliparous 1.44 1.21, 1.71 1.74 1.08, 2.82 1.24 1.15, 1.34 1.32 1.09, 1.60
P for trend <0.01 0.03 <0.01 <0.01
Age at menopause, years 0.03 <0.01 0.36
<45 1.51 1.15, 1.97 0.77 0.35, 1.73 0.81 0.71, 0.93 0.74 0.53, 1.04
45–49 1.08 0.87, 1.34 0.62 0.35, 1.12 0.92 0.84, 1.00 0.97 0.78, 1.21
50–54 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
≥55 1.33 1.00, 1.75 0.59 0.25, 1.39 1.22 1.09, 1.36 1.34 1.03, 1.75
Surgical 1.01 0.84, 1.21 0.41 0.25, 0.67 0.71 0.66, 0.77 0.75 0.62, 0.91
Unknown 1.55 1.07, 2.23 0.78 0.30, 1.99 0.93 0.77, 1.12 0.60 0.34, 1.03
P for trend 0.28 0.03 <0.01 0.08
MHT use 0.06 0.23 0.01
Never 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Former 1.17 0.90, 1.52 1.70 0.76, 3.79 1.08 0.97, 1.21 0.95 0.71, 1.28
Current (<5 years) 1.56 1.26, 1.95 2.72 1.47, 5.02 1.23 1.12, 1.35 1.42 1.13, 1.80
Current (5–9 years) 1.89 1.53, 2.32 4.62 2.66, 8.05 1.49 1.36, 1.64 1.50 1.19, 1.89
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Table 3. Continued
Characteristic
DCIS (n = 865) LCIS (n = 113) DCIS vs. LCIS
P for Heterogeneity
IDC (n = 4,592) DCIS vs. IDC
P for Heterogeneity
ILC (n = 734) LCIS vs. ILC
P for HeterogeneityHR 95%CI HR 95%CI HR 95%CI HR 95%CI
Current (≥10 years) 1.59 1.30, 1.93 3.32 1.83, 6.01 1.43 1.32, 1.56 1.42 1.15, 1.75
P for trend <0.01 <0.01 <0.01 <0.01
Family history of breast cancer 0.90 0.58 0.47
No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Yes 1.57 1.32, 1.87 1.43 0.87, 2.35 1.48 1.37, 1.60 1.26 1.03, 1.54
Breast biopsy 0.22 0.10 0.16
No 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Yes 1.51 1.31, 1.74 2.08 1.42, 3.03 1.34 1.26, 1.43 1.54 1.32, 1.80
Alcohol consumption, g/day 0.96 0.64 0.95
0 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
0.01–10.00 1.16 0.99, 1.37 1.15 0.73, 1.83 1.05 0.98, 1.13 1.01 0.85, 1.21
10.01–20.00 1.29 1.00, 1.65 1.40 0.71, 2.73 1.13 1.01, 1.26 1.12 0.86, 1.47
≥20.01 1.20 0.91, 1.59 1.11 0.49, 2.50 1.22 1.09, 1.37 1.28 0.96, 1.69
P for trend 0.06 0.53 <0.01 0.09
Smoking status 0.29 0.71 0.30
Never 1.00 Referent 1.00 Referent 1.00 Referent 1.00 Referent
Former 1.06 0.91, 1.22 0.74 0.49, 1.13 1.11 1.04, 1.18 1.10 0.93, 1.29
Current 1.03 0.83, 1.28 0.81 0.43, 1.50 1.14 1.04, 1.25 1.27 1.01, 1.58
P for trend 0.57 0.27 <0.01 0.04
Abbreviations: BMI, bodymass index; CI, confidence interval; DCIS, ductal carcinoma in situ; HR, hazard ratio; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular
carcinoma in situ; MHT, menopausal hormone therapy.
a All analyses were adjusted for age at entry, race, body mass index, smoking status, alcohol consumption, age at menarche, age at first birth, age at menopause, MHT use and duration of
use, past breast biopsy, family history of breast cancer in a first-degree female relative, educational level, and frequency of vigorous physical activity.
b The women had a mammogram within the 3 years before completion of the second study follow-up questionnaire. Follow-up for this analysis involved mammographic screening data cap-
tured on the second study questionnaire, and follow-up for this analysis began on the date on which that questionnaire was returned.
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that among this population, early age at natural menopause
was still associated with a higher risk of DCIS but not LCIS
(for DCIS, HR = 1.51, 95% CI: 1.15, 1.97; P for heteroge-
neity = 0.03) or IDC (HR = 0.81, 95% CI: 0.71, 0.93; P for
heterogeneity< 0.01). In addition, current MHT use was still
most strongly associated with a higher risk of LCIS than of
ILC (P for heterogeneity = 0.01).
DISCUSSION
Within the NIH-AARPDiet and Health Study, we identified
many similarities in and a few differences between associations
of breast cancer risk factors with incident in situ and invasive
breast cancers among postmenopausal women. Although asso-
ciations were similar for race, age at menarche, age at first
birth, a family history of breast cancer, and lifestyle factors
(BMI, alcohol use, cigarette smoking status, and level of
physical activity), we observed significant heterogeneity in
risk associated with age at natural menopause, MHT use, and a
history of breast biopsy. In particular, higher risks associated
with MHT use and previous breast biopsy were stronger for
LCIS than for ILC andDCIS, respectively. These findings sug-
gest that most risk factors for breast cancer act at the precursor
stage, but there may be a few with differential associations for
in situ versus invasive breast cancers.
There have been few longitudinal studies in which investi-
gators have examined associations between risk factors and
LCIS. Our findings, which demonstrated similar risk patterns in
the associations of race, age atmenarche, age at first birth, family
history, alcohol use, and smoking status with both DCIS and
LCIS, suggest that these noninvasive lesions may share at least
some common etiology. Given that cases of LCIS and low-grade
DCIS are nearly uniformly estrogen receptor (ER)–positive,
comparisons might have been tighter had grade information
been available. Our findings also suggest some possible eti-
ological differences: Differences in patterns of association
were observed for age at natural menopause and risk of DCIS
versus LCIS. Our findings are consistent with those from a pre-
vious analysis by Claus et al. (21) but were not in agreement
with results from a case-control study that showed a lower risk
of DCIS associatedwith younger age atmenopause (22). Among
women who experienced menopause at a younger age, we
observed a significantly higher risk of DCIS but not LCIS. One
possible biological hypothesis for this finding may be accounted
for by the relationship between decreasedmammographic breast
density andmenopause (23). Highermammographic breast den-
sity is associated with lower mammographic sensitivity (24). A
possible implication of youngermenopausal age is thatmammo-
graphic density will have also declined at a younger age, which
potentially renders DCISmore visible on a mammogram during
screening. Because LCIS are less frequently detected with mam-
mography, it is not necessarily surprising that this association
was not observed for LCIS. This is supported by the findings in
our sensitivity analysis, which showed even higher hazard ratios
for the association of DCIS with a younger age at menopause
compared with the association with LCIS when the population
was restricted towomenwho reported a previous mammogram
in the 3 years prior to the second study follow-up question-
naire. However, because measurements of mammographic
breast density were not available for analysis among this study
population, we cannot directly investigate this hypothesis.
Because multiple statistical tests were carried out, we also
acknowledge that this finding may be spurious.
In addition, we found that current MHT use was more
strongly associated with the risk of LCIS than with the risk
of DCIS, findings that are of a similar magnitude to a previ-
ous analysis within the prospective cohort from the Million
Women Study (MWS), although a larger number of LCIS
cases were included in this present analysis than in the previous
report (5). Further within the Million Women Study, Reeves
et al. (5) showed strong relationships between MHT use and
increased risks of both DCIS (n = 1,443) and LCIS (n = 86).
In addition, in our prospective analysis we showed a stronger
association of previous benign breast biopsy with LCIS risk
than with DCIS, which is in agreement with results from 3
population-based case-control studies (6, 7, 21). The observed
associations between a history of benign breast biopsy and an
elevated risk of in situ lesions are complex and likely due to the
influence of multiple factors. For example, these findings may
be driven by biological mechanisms relating benign lesions to
the risk of subsequent development of in situ lesions. Further-
more, these associations may be the result of higher surveil-
lance among women who would have had a prior biopsy than
among women who did not.
DCIS is widely accepted as a nonobligate precursor of IDC,
and both are thought to share common etiologies, as reviewed
by Virnig et al. (25). In a second analysis conducted with the
prospective cohort from the Million Women Study, Reeves
et al. (26) compared risk factors for DCIS and IDC among that
cohort of 1.1 million postmenopausal women from the United
Kingdom, which included 3,715 women with DCIS and
21,137 with IDC. Similar to our findings, significant heteroge-
neity was not observed between the risks of DCIS and IDC for
most breast cancer risk factors, including age at menarche, age
at first birth, MHT use, and a family history of breast cancer
(26). However, in that prior study, investigators observed stron-
ger associations of higher BMI and alcohol consumption with
an increased risk of IDC than with DCIS (26). Although we
observed somewhat stronger positive associations of BMI and
alcohol consumption with the risk of IDC versus the risk of
DCIS, the test for statistical heterogeneity was null in our study
population.
The role of LCIS as a precursor lesion of ILC is less well
understood (27). It is a less common histological type, it is
often not recognized radiologically, and its classification is
often surrounded by inconsistency (28). However, multiple
studies have shown that LCIS is associated with an increased
risk of invasive breast cancer (29–32). The most notable dif-
ferences between LCIS and ILC risks in our analyses were
observed for MHT use, with significantly stronger associa-
tions with the risk of LCIS than with ILC, findings that were
also observed in our sensitivity analysis restricted to women
who had undergone a mammogram. Several lines of evidence
support a hormonal influence on the development of LCIS.
First, incidence trends for LCIS in the United States declined
sharply between 2001 and 2004 (27, 33), which is likely the
result of decreased use of MHT after the publication of results
from the Women’s Health Initiative (8). In addition, findings
from the National Surgical Adjuvant Breast and Bowel Project
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P-1 chemoprevention trial highlighted the potential for the
selective ERmodulator tamoxifen to reduce the development
of LCIS (34), and the American Society for Clinical Oncology
guidelines include recommendations for antiestrogen therapy
as chemoprevention for future breast cancer risk among women
with LCIS (35).
A strength of the present study was the large number of cases
and extended follow-up period (through 2011). Although the
NIH-AARP Diet and Health Study is population-based, it was
geographically restricted.Most participants were older, with the
largest proportion of women 65 years of age or older, which
may limit the generalizability of these findings among younger
postmenopausal women. In addition, compared with the other
histological types assessed, the number of LCIS cases was
somewhat limited. Despite this limitation, our study highlighted
higher risks associated with current MHT use, particularly for
LCIS. Because prior work has demonstrated differential asso-
ciations of breast cancer risk by MHT formulation (e.g., estro-
gen alone vs. combined estrogen plus progestin) (5, 17, 36),
future efforts in larger diverse populations are needed to exam-
ine these relationships in order to further understand the risks
of in situ and invasive breast cancers associated with specific
MHT formulations. Furthermore, although the majority of
breast cancers diagnosed in older women are ER-positive, we
were unable to directly examine associations of risk factors
specifically for pathologically confirmed ER-positive breast
cancers. ER status was not systematically reported in Florida,
Texas, and Pennsylvania registries. In addition, ER classifica-
tion of in situ breast cancer was not routinely recorded in regis-
tries until recently, with ER status for DCIS in the data captured
by the Surveillance, Epidemiology, and End Results Program
only reaching 72% completeness in 2005 (37, 38). Further-
more, within our analysis, a large number of statistical tests for
heterogeneity were carried out; therefore, we cannot eliminate
the possibility that findings may be the result of chance.
In conclusion, we found that associations of many breast
cancer risk factors with in situ and invasive carcinomas were
similar, which suggest that most risk factors act during the early
stages of breast tumorigenesis. However, certain associations
differed between in situ and invasive breast cancers, which may
suggest that some factors act differentially during the in situ
stage or that there are possibly unaccounted for effects, such as
detectability by mammography. These similarities and differ-
ences are important in order to increase our understanding of
the etiology of histological tumor types and may help to inform
prevention strategies. Future ongoing work will determine the
importance of these risk factors among women who are diag-
nosed with an in situ lesion and subsequently develop an inva-
sive breast cancer at a later time point. Additional studies that
include distinct molecular subtypes are required to expand these
findings to further understand the role ofMHT use, menopausal
age, and benign breast disease in breast carcinogenesis.
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